Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Though lung cancer looks promising a partner is now needed.
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
Regeneron is facing two FDA decisions for its T-cell engagers.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
